Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer. (April 2016)

• Record Type: Journal Article
• Authors: Sullivan, Ivana; Planchard, David
• Is Part Of: Future oncology. Volume 12:Number 7(2016)
• Page Start: 945
• Page End: 961
• Publication Date: 2016-04
• Subjects: alectinib -- ALK-rearrangement -- CNS disease -- ceritinib -- crizotinib -- crizotinib-resistance -- non-small-cell lung cancer; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.16.15
• Languages: English
• ISSNs: 1479-6694

Abstract

The ALK gene plays a key role in the pathogenesis of non-small-cell lung cancer (NSCLC). Patients with NSCLC harboring an ALK -rearrangement represent the second oncogene addiction to be identified in this disease. Crizotinib was the first ALK inhibitor showing pronounced clinical activity, and is now a reference treatment for ALK -positive NSCLC disease. However, despite initial impressive responses to crizotinib, acquired resistance almost invariably develops within 12 months. The pressing need for effective second-line agents has prompted the rapid development of next-generation ALK inhibitors. These agents, notably ceritinib and alectinib as the most developed, have a higher potency against ALK than crizotinib, along with activity against tumors harboring crizotinib-resistant mutations and potentially improved CNS penetration.